TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04822649

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Adenosine stress echocardiography with the evaluation of coronary artery blood flow
Description: The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis.
Study: NCT06178445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC plus trastuzumab and pembrolizumab
Description: SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
Study: NCT05510154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: A single, brief advice session on switching to electronic cigarettes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Training
Description: A single, in-depth training session on switching to electronic cigarettes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training to Competency
Description: Multiple, in-depth training sessions on switching to electronic cigarettes.
Study: NCT04762641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL503
Description: ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study: NCT02900079

Intervention type: DEVICE
Intervention: rapid diagnostic test for malaria antigen
Description: rapid diagnostic test for malaria antigen to be used by travelers when febrile
Study: NCT05014360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablets will be administered orally.
Study: NCT05058755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab, azacytidine, lenalidomide
Description: tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab, etoposide, pegaspargase
Description: tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days
Study: NCT06208384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin eye drop
Description: Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Study: NCT03932656

Intervention type: BEHAVIORAL
Intervention: Combined schema-therapy and cognitive behavioral therapy
Description: A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.

Intervention type: DRUG
Intervention: Psychopharmaceuticals
Description: Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
Study: NCT05794165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombate infusion
Description: Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Study: NCT05104645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of the walk
Description: Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of the walk
Description: Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of the race
Description: Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unipodal and bipodal jumps on flat ground
Description: Healthy volunteers: 2 times (between 3 and 20 days apart)
Study: NCT06433830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.
Study: NCT05584670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445877
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Solution for infusion
Study: NCT01865630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
Study: NCT05488210

Intervention type: DIETARY_SUPPLEMENT
Intervention: FontActiv DiaBest HP/HC
Description: Daily intake of two FontActiv DiaBest HP/HC during 2 months
Study: NCT05111262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
Description: In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
Study: NCT05342662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light-blocking glasses
Description: Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glasses with clear lenses
Description: Non-blue light-blocking glasses
Study: NCT04932850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAD0004J08
Description: Human mAb 100 mg / 2.5 mL solution for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to MAD0004J08 2.5 mL solution for injection
Study: NCT06132165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deoxycholic Acid
Description: Injection into the cutaneous Neurofibromas lesion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol
Description: Injection into the cutaneous Neurofibromas lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064nm Nd:YAG laser
Description: Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 755nm Alexandrite Laser
Description: Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
Study: NCT06242379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMP compliant-BM-MSC derived sEVs
Description: The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
Study: NCT05954923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino acid bolus infusion
Description: Equimolar bolus infusions of amino acids or saline (placebo)
Study: NCT04912245

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth visit
Description: Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
Study: NCT05726851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2025
Description: E2025 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2025 matched placebo IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2025 matched placebo IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2025 matched placebo IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2025 matched placebo IV infusion.
Study: NCT06295341

Intervention type: DRUG
Intervention: Recombinant human growth hormone (only for children with growth hormone deficiency)
Description: 6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
Study: NCT05788887

Intervention type: OTHER
Group type: OTHER
Intervention: Authentic Ladotyri Mytilinis PDO cheese
Description: Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
Study: NCT05919654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoCare
Description: Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearView
Description: Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
Study: NCT05097521

Intervention type: OTHER
Intervention: Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
Description: Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings

Intervention type: OTHER
Intervention: Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
Description: Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings

Intervention type: OTHER
Intervention: Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
Description: Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
Study: NCT05281133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group using virtual reality glasses
Description: The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
Study: NCT05220397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Janssen Ad26.CoV2.S Vaccine
Description: Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Janssen Ad26.CoV2.S Vaccine
Description: Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction in Immunosuppression Medication
Description: Reduction in immunosuppression medication dosage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction in Immunosuppression Medication
Description: Reduction in immunosuppression medication dosage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance in Immunosuppression Medication
Description: Maintain current immunosuppression medication dosage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance in Immunosuppression Medication
Description: Maintain current immunosuppression medication dosage
Study: NCT05210283

Intervention type: DEVICE
Intervention: MRD
Description: ctDNA MRD test
Study: NCT05753267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 160mg
Description: Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
Study: NCT06303284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Teriparatide injection
Description: 20 µg subcutaneous (SC) Teriparatide injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
Study: NCT05501938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Exam Indicated Cerclage
Description: Transvaginal cervical cerclage
Study: NCT04472520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor Heart Monitor
Description: Records single-channel ECG rhythms
Study: NCT05284279

Intervention type: OTHER
Intervention: Exploring health professionals' perceptions of patients with ECC using semi-structured interviews
Description: Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences.
Study: NCT05001984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab
Description: Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
Study: NCT06537648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome Program
Description: Adults with Down syndrome will be asked to attend 35 minute, remotely delivered (Zoom®) group dance sessions twice weekly across 12 weeks. All sessions will be directed by an instructor experienced in leading 35 minute, group remote exercise sessions for individuals with intellectual disability as part of the ongoing exercise program for individuals with intellectual disability offered by the Division for Physical Activity and Weight Management.
Study: NCT03988231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receipt of enoxaparin
Description: Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
Study: NCT04646785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy + TAU
Description: The proposed intervention is mindfulness-based cognitive therapy (MBCT), based on the protocol published by Segal, Williams and Teasdale. MBCT consists of eight weekly 2.5h group sessions, a six-hour silent day and daily home practice assignments guided by audio files. The program includes both formal and informal meditation exercises. Cognitive techniques include monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan. Psycho-education and interactive dialogue typically focus on stress management, balancing activities, and (lifestyle) strategies to stay well in the future (relapse prevention).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU) according Dutch and European IBD treatment guidelines. TAU focuses on pharmacological and surgical disease control, and prevention of complications.
Study: NCT06226311

Intervention type: OTHER
Intervention: Data collection
Description: Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years

Intervention type: OTHER
Intervention: Diagnostic Test: Urinary
Description: Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
Study: NCT04533490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months